BioTime and its wholly owned subsidiary, LifeMap Sciences, have announced an agreement to purchase XenneX.
The acquisition, which is expected to close within 30 days, will merge XenneX into LifeMap Sciences.
The deal is expected to integrate GeneCards and PanDaTox in a centralized resource called LifeMap.
BioTime chief executive officer Michael West said, "We believe that centralized online databases of biological knowledge will become indispensable tools for research in the field of regenerative medicine."
LifeMap Sciences will use new family of online databases to promote the sale of stem cell research products and for discovery of regenerative medicine therapeutic products, based on BioTime's ACTCellerate human progenitor cell lines.
LifeMap Sciences chief executive officer David Warshawsky said, "LifeMap has made great progress with the LifeMap database and discovery platform, and we see GeneCards(R), MalaCards and PanDaTox as a perfect fit for making LifeMap the leading source of online database research tools for genetic, biological, and stem cell research and development."
